Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)

NCT04047628 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT04047628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04047628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 3
Overall status
Recruiting
Start date
August 17, 2020
Completion date
October 31, 2029
Enrollment
156 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis, relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis